Literature DB >> 6616336

Interaction of histamine with noradrenergic constrictory mechanisms in cat cerebral arteries and veins.

P M Gross, A M Harper, G M Teasdale.   

Abstract

We examined responses of pial arteries and veins in situ to noradrenergic stimuli in the presence of histamine. Electrical stimulation of sympathetic nerves and perivascular microapplication of norepinephrine in mock cerebrospinal fluid produced constriction of arteries and veins in anesthetized cats. During simultaneous perivascular injection of histamine, these noradrenergic responses were attenuated or reversed. In both arteries and veins, constriction from sympathetic nerve stimulation was prevented by simultaneous application of the histamine receptor agonists, pyridylethylamine (H1) or impromidine (H2), results that suggest interference involving both types of histamine receptors. In arteries, impromidine, but not pyridylethylamine, inhibited constriction resulting from exogenous norepinephrine. Our findings indicate that histamine may have an inhibitory influence, exerted through both receptor types, on noradrenergic mechanisms in cerebral vessels.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6616336     DOI: 10.1139/y83-117

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  3 in total

1.  Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride.

Authors:  Aaron A Phillips; Darren E R Warburton; Philip N Ainslie; Andrei V Krassioukov
Journal:  J Cereb Blood Flow Metab       Date:  2014-01-29       Impact factor: 6.200

Review 2.  Why is the neural control of cerebral autoregulation so controversial?

Authors:  Philip N Ainslie; Patrice Brassard
Journal:  F1000Prime Rep       Date:  2014-03-03

Review 3.  Cerebral oxygenation and hyperthermia.

Authors:  Anthony R Bain; Shawnda A Morrison; Philip N Ainslie
Journal:  Front Physiol       Date:  2014-03-04       Impact factor: 4.566

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.